Quality Improvement through Advisory, Review and Partner Collaboration Councils
First written in FY2018. 8 of 10 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2026-H1.
The whole theme swung hardest in 2026: 7 of 52 companies on the "Worse" side.
34 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「At this academic conference, in addition to exhibiting a booth, the Company held a co-hosted seminar chaired by Hisae Hayashi (林久恵), Professor at the Faculty of Health and Medical Sciences, Aichi Shukutoku University. Yoshifumi Moriyama (森山善文) of the Rehabilitation Department of Nagoya Kyoritsu Hospital, Kaikoukai Medical Corporation, and Shinobu Ayabe (綾部忍) of Yao Tokushukai General Hospital, Tokushukai Medical Corporation, presented evidence concerning rehabilitation interventions using SIXPAD for dialysis patients under the theme "The Potential of Dialysis Rehabilitation Using SIXPAD."」
The Company exhibited a booth and held a co-hosted seminar at a medical conference, communicating evidence on the use of SIXPAD for dialysis patients to healthcare professionals. - FY2025AdvancedAnnual report
「As a countermeasure, the Group has strengthened cooperation with manufacturing partners, established a system to ensure performance from the early stages of development, and conducts on-site quality audits to secure manufacturing processes. In addition, it has introduced a product review committee system in which advisors with specialist knowledge of quality and development participate in new-product development.」
In addition to its existing advisors, review committees and academic evidence, the Company explicitly described cooperation with manufacturing partners from the early development stage and on-site quality audits. - FY2024AdvancedAnnual report
「In August 2024, the Company exhibited a booth at the Measurement and Automatic Control Society of Japan's Life Engineering Division Symposium 2024 (LE2024), held at the Neyagawa Campus of Osaka Electro-Communication University, providing an opportunity to experience its products and introducing previously obtained EMS evidence and papers.」
The Company continues to exhibit at academic conferences and symposia, offer product experiences and introduce EMS evidence and papers, using research results to communicate product and brand value. - FY2024-Q2AdvancedAnnual report
「Activities pursuing the further potential of fine-bubble technology are also expanding. For example, a study on the usefulness of fine-bubble washing for canine atopic dermatitis, which was accepted for publication in an international paper, was presented at the Nikkei Business Innovation Forum hosted by Nikkei Inc.」
A study of fine-bubble washing for canine atopic dermatitis was accepted for publication in an international paper and presented at a forum, advancing evidence-based and applied research on fine-bubble technology. - FY2023-Q1AdvancedAnnual report
「The results of joint research with Kanazawa University on skeletal-muscle electrical stimulation and cognitive function were published in the international journal European Journal of Applied Physiology. The study confirmed that the concentration of blood BDNF (brain-derived neurotrophic factor) increases as the amount of muscle stimulated by EMS increases, and that BDNF expression continues to increase for approximately 20 minutes. It also demonstrated that stimulating the lower leg (calf) is more effective than stimulating the thigh. Going forward, the Company will focus on contributing to the resolution of social issues in the HEALTH CARE category.」
The results of joint research with Kanazawa University were published in an international journal, disclosing specific findings concerning EMS, BDNF and stimulation sites. - FY2022RestatedAnnual report
「The Group develops its brands and products with a rigorous focus on obtaining academic evidence concerning their efficacy and effects.」
The Company continues its quality and research policy of developing products based on academic evidence. - FY2022-Q1AdvancedAnnual report
「At the Japanese Society for Chronobiology conference in November 2021, the Company presented data showing improved sleep-measurement accuracy and links to improved sleep as evidence for the contactless sleep sensor incorporated in AI Motion Mattress.」
The Company presented at an academic conference data on the contactless sleep sensor in AI Motion Mattress showing improved sleep-measurement accuracy and links to improved sleep. - FY2021AdvancedAnnual report
「The Group develops its brands and products with a rigorous focus on obtaining academic evidence concerning their efficacy and effects.」
In addition to quality control through advisory, product review and partner cooperation committees, the Company emphasised obtaining academic evidence concerning efficacy and effects as an explicit product-development initiative. - FY2021-Q2AdvancedAnnual report
「In February 2021, the Company also established FINE BUBBLE LABO, a website dedicated to pursuing and verifying the potential of the fine-bubble technology used in ReFa FINE BUBBLE S in the beauty field, and began initiatives to contribute to the further sound development and revitalisation of the fine-bubble industry.」
The Company established FINE BUBBLE LABO and began quality and research activities aimed at verifying the technology and promoting the sound development and revitalisation of the industry. - FY2018First statedAnnual report
「In product development, the Company has introduced a product review committee system that makes review by advisors mandatory, rather than merely consulting them. Through these initiatives, it manufactures high-quality products, and to accelerate overseas expansion it will establish systems and develop personnel capable of developing even higher-quality products.」
The Company described a quality-control framework involving an advisory committee of external experts, a product review committee and a partner cooperation committee with contract manufacturers.